Latest / Cell & Gene: The Podcast

Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness
We love to hear from our listeners. Send us a message.
In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust immune response with minimal side effects. He highlights results from a multicenter Phase 2B trial showing…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.